Cargando…

A 24‐Week, Randomized, Controlled Trial of Rivastigmine Patch 13.3 mg/24 h Versus 4.6 mg/24 h in Severe Alzheimer's Dementia

AIMS: The 24‐week, prospective, randomized, double‐blind ACTION study investigated the efficacy, safety, and tolerability of 13.3 versus 4.6 mg/24 h rivastigmine patch in patients with severe Alzheimer's disease (AD). METHODS: Patients had probable AD and Mini–Mental State Examination scores ≥3...

Descripción completa

Detalles Bibliográficos
Autores principales:	Farlow, Martin R., Grossberg, George T., Sadowsky, Carl H., Meng, Xiangyi, Somogyi, Monique
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2013
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4233957/ https://www.ncbi.nlm.nih.gov/pubmed/23924050 http://dx.doi.org/10.1111/cns.12158

Ejemplares similares

Efficacy of 13.3 mg/24 h versus 4.6 mg/24 h rivastigmine patch on activities of daily living in severe Alzheimer’s disease
por: Micca, Joseph L, et al.
Publicado: (2014)

Responder analysis of a randomized comparison of the 13.3 mg/24 h and 9.5 mg/24 h rivastigmine patch
por: Molinuevo, José L, et al.
Publicado: (2015)

A Case Report on Dyskinesia Following Rivastigmine Patch 13.3 mg/24 hours for Alzheimer's Disease: Perspective in the Movement Disorders Spectrum Following Use of Cholinesterase Inhibitors
por: Diaz, Maria Cristina B., et al.
Publicado: (2015)

The Effect of Vascular Risk Factors on the Efficacy of Rivastigmine Patch and Capsule Treatment in Alzheimer's Disease
por: Farlow, M.R., et al.
Publicado: (2011)

Laser Cooling of $^{24}$Mg$^{+}$ in the ASTRID Storage Ring
por: Nielsen, J S, et al.
Publicado: (1994)

A 24-Week, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety and Tolerability of the Rivastigmine Patch in Japanese Patients with Alzheimer's Disease
por: Nakamura, Yu, et al.
Publicado: (2011)

Once-weekly 2.4 mg Semaglutide for Weight Management in Obesity: A Game Changer?
por: Colin, Ides M, et al.
Publicado: (2022)

Comparing Clinical Profiles in Alzheimer's Disease and Parkinson's Disease Dementia
por: Farlow, Martin R., et al.
Publicado: (2013)

High resolution study of $^{24}$Mg(p,d)$^{23}$Mg for the Ne-E problem
por: Kubono, S, et al.
Publicado: (1994)

Flow and multifragmentation of $^{24}$Mg + $^{27}$Al at intermediate energies
por: Prendergast, E P, et al.
Publicado: (1999)

Measurement of the $^{24}Mg(p,t)^{22}Mg$ reaction for the states near the $^{21}Na+p$ threshold
por: Michimasa, S, et al.
Publicado: (2002)

Comparison of INTAKE24 (an Online 24-h Dietary Recall Tool) with Interviewer-Led 24-h Recall in 11–24 Year-Old
por: Bradley, Jennifer, et al.
Publicado: (2016)

Dynamic IMF production in $^{24}Mg + ^{27}Al$ at intermediate energies
por: Prendergast, E P, et al.
Publicado: (1999)

Study of binary reaction channels in the ${24}Mg$ + ${12}C$ collision
por: Sánchez i Zafra, A, et al.
Publicado: (2005)

Efficacy and Safety of Once-Weekly Subcutaneous Semaglutide 2.4 MG in Adults With Overweight or Obesity (STEP 1)
por: Wilding, John P H, et al.
Publicado: (2021)

The Impact Once-Weekly Semaglutide 2.4 mg Will Have on Clinical Practice: A Focus on the STEP Trials
por: Alabduljabbar, Khaled, et al.
Publicado: (2022)

Once-Weekly Subcutaneous Semaglutide 2.4 mg Injection is Cost-Effective for Weight Management in the United Kingdom
por: Sandhu, Hera, et al.
Publicado: (2023)

A 24-Week, Randomized, Controlled Study to Evaluate the Tolerability, Safety and Efficacy of 2 Different Titration Schemes of the Rivastigmine Patch in Japanese Patients with Mild to Moderate Alzheimer's Disease
por: Nakamura, Yu, et al.
Publicado: (2015)

Spin polarization of $^{23}$Mg in $^{24}$Mg + Au, Cu and Al collisions at 91 A MeV
por: Matsuta, K, et al.
Publicado: (1994)

Rivastigmine in moderately severe-to-severe Alzheimer’s disease: Severe Impairment Battery factor analysis
por: Ferris, Steven, et al.
Publicado: (2013)

Evaluation of the cross sections for the reactions $^{24}Mg(n,p)^{24}Na^{64}Zn(n,p)^{64}Cu$...
por: Strohmaier, B, et al.
Publicado: (1979)

Pharmacokinetics of a novel transdermal rivastigmine patch for the treatment of Alzheimer’s disease: a review
por: Kurz, A, et al.
Publicado: (2009)

A Randomized Study of Lenvatinib 18 mg vs 24 mg in Patients With Radioiodine-Refractory Differentiated Thyroid Cancer
por: Brose, Marcia S, et al.
Publicado: (2021)

Cluster-decay of hot $^{56}Ni$ formed in $^{32}S$+$^{24}Mg$ reaction
por: Gupta, R K, et al.
Publicado: (2002)

Cluster decay of hot $^{56}Ni*$ formed in $^{32}S+^{24}Mg$ reaction
por: Gupta, R K, et al.
Publicado: (2003)

Comparison of a Web-Based 24-h Dietary Recall Tool (Foodbook24) to an Interviewer-Led 24-h Dietary Recall
por: Timon, Claire M., et al.
Publicado: (2017)

The effect of semaglutide 2.4 mg once weekly on energy intake, appetite, control of eating, and gastric emptying in adults with obesity
por: Friedrichsen, Martin, et al.
Publicado: (2021)

Efficacy and Safety of Semaglutide 2.4 MG Once-Weekly in Adults With Overweight or Obesity and Type 2 Diabetes (STEP 2)
por: Davies, Melanie, et al.
Publicado: (2021)

Clinical efficacy of 60-mg dexlansoprazole and 40-mg esomeprazole after 24 weeks for the on-demand treatment of gastroesophageal reflux disease grades A and B: a prospective randomized trial
por: Chiang, Hung-Hsien, et al.
Publicado: (2019)

Corrosion Resistance of Mg(72)Zn(24)Ca(4) and Zn(87)Mg(9)Ca(4) Alloys for Application in Medicine
por: Fijołek, Andrzej, et al.
Publicado: (2020)

Weight Loss Maintenance With Once-Weekly Semaglutide 2.4 MG in Adults With Overweight or Obesity Reaching Maintenance Dose (STEP 4)
por: Rubino, Domenica M, et al.
Publicado: (2021)

Changes in Glucose Metabolism and Glycemic Status With Once-Weekly Subcutaneous Semaglutide 2.4 mg Among Participants With Prediabetes in the STEP Program
por: Perreault, Leigh, et al.
Publicado: (2022)

Development of a UK Online 24-h Dietary Assessment Tool: myfood24
por: Carter, Michelle C., et al.
Publicado: (2015)

Time scale in $^{24}$Mg projectile breakup at 25A and 35A MeV
por: Samri, M, et al.
Publicado: (1995)

Semaglutide 2.4 mg for the Treatment of Obesity: Key Elements of the STEP Trials 1 to 5
por: Kushner, Robert F., et al.
Publicado: (2020)

Semaglutide 2.4 Mg for the Management of Overweight and Obesity: Systematic Literature Review and Meta-Analysis
por: Smith, Inger, et al.
Publicado: (2022)

Rivastigmine for minor visual hallucinations in Parkinson's disease: A randomized controlled trial with 24 months follow‐up
por: van Mierlo, Tom J. M., et al.
Publicado: (2021)

Efficacy, Safety, and Tolerability of Switching from Oral Cholinesterase Inhibitors to Rivastigmine Transdermal Patch with 1-Step Titration in Patients with Mild to Moderate Alzheimer's Disease: A 24-Week, Open-Label, Multicenter Study in Japan
por: Ueda, Kengo, et al.
Publicado: (2019)

Continuous growth reference from 24(th )week of gestation to 24 months by gender
por: Niklasson, Aimon, et al.
Publicado: (2008)

Abstract 10: Efficacy and safety of semaglutide 2.4 mg once- weekly in adults with overweight or obesity and type 2 diabetes (STEP 2)
por: Rahman, Syed Kasfur, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_ggompd8gj44mbo5tj0r98r5bi9